- Home
- APPS vs MXCT Comparison
APPS vs MXCT Comparison
Compare APPS & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- MXCT
- Stock Information
- Founded
- APPS N/A
- MXCT 1999
- Country
- APPS United States
- MXCT United States
- Employees
- APPS N/A
- MXCT N/A
- Industry
- APPS Multi-Sector Companies
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- APPS Miscellaneous
- MXCT Health Care
- Exchange
- APPS Nasdaq
- MXCT Nasdaq
- Market Cap
- APPS 428.8M
- MXCT 474.6M
- IPO Year
- APPS N/A
- MXCT 2021
- Fundamental
- Price
- APPS $2.92
- MXCT $4.22
- Analyst Decision
- APPS Hold
- MXCT Strong Buy
- Analyst Count
- APPS 2
- MXCT 3
- Target Price
- APPS $5.25
- MXCT $8.67
- AVG Volume (30 Days)
- APPS 3.4M
- MXCT 312.9K
- Earning Date
- APPS 11-06-2024
- MXCT 11-06-2024
- Dividend Yield
- APPS N/A
- MXCT N/A
- EPS Growth
- APPS N/A
- MXCT N/A
- EPS
- APPS N/A
- MXCT N/A
- Revenue
- APPS $516,105,000.00
- MXCT $45,439,000.00
- Revenue This Year
- APPS $2.50
- MXCT N/A
- Revenue Next Year
- APPS $9.57
- MXCT $24.75
- P/E Ratio
- APPS N/A
- MXCT N/A
- Revenue Growth
- APPS N/A
- MXCT 11.69
- 52 Week Low
- APPS $1.39
- MXCT $2.45
- 52 Week High
- APPS $7.33
- MXCT $5.55
- Technical
- Relative Strength Index (RSI)
- APPS 48.98
- MXCT 48.19
- Support Level
- APPS $2.57
- MXCT $3.72
- Resistance Level
- APPS $2.99
- MXCT $4.15
- Average True Range (ATR)
- APPS 0.23
- MXCT 0.19
- MACD
- APPS -0.09
- MXCT 0.00
- Stochastic Oscillator
- APPS 33.47
- MXCT 49.30
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.